Dual antiplatelet therapy—the combination of aspirin and a P2Y 12-receptor inhibitor—is the
cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those …

The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing
percutaneous coronary intervention with stent implantation is an emerging clinical problem …

Background Elderly patients are at high risk of ischaemic and bleeding events. Platelet
function monitoring offers the possibility to individualise antiplatelet therapy to improve the …

Hellmut Hartert was the first person to exploit the viscoelastic properties of clotting blood to
measure blood coagulation in 1948. Since then, the technology has improved, allowing …

The pivotal role that platelets play in thrombosis and resultant ischemic event occurrences in
patients with high-risk coronary artery disease is well established. This role provides the …

Objectives: The study sought to compare the clinical efficacy and safety of P2Y12 inhibitors
in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary …

Guidelines provide a Class IA recommendation for the use of dual antiplatelet therapy in
patients undergoing percutaneous coronary intervention (PCI). However, there is …

Abstract Treatment of carriers of the CYP2C19* 2 allele and ABCB1 TT genotype with
clopidogrel is associated with increased ischemic complications after percutaneous …

Objectives Low response to antiplatelet drugs is one of the risk factors for ischemic events.
We examined the influence of low response to clopidogrel on symptomatic ischemic events …

Aims In vivo platelet function is a product of intrinsic platelet reactivity, modifiable by dual
antiplatelet therapy (DAPT), and the extrinsic inhibitory endothelial mediators, nitric oxide …